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Bromodomain-PHD ﬁnger protein 1 (BRPF1) is part of the MOZ HAT complex and contains a unique
combination of domains typically found in chromatin-associated factors, which include plant
homeodomain (PHD) ﬁngers, a bromodomain and a proline-tryptophan-tryptophan-proline
(PWWP) domain. Bromodomains are conserved structural motifs generally known to recognize
acetylated histones, and the BRPF1 bromodomain preferentially selects for H2AK5ac, H4K12ac and
H3K14ac. We solved the X-ray crystal structures of the BRPF1 bromodomain in complex with the
H2AK5ac and H4K12ac histone peptides. Site-directed mutagenesis on residues in the BRPF1
bromodomain-binding pocket was carried out to investigate the contribution of speciﬁc amino acids
on ligand binding. Our results provide critical insights into the molecular mechanism of ligand
binding by the BRPF1 bromodomain, and reveal that ordered water molecules are an essential
component driving ligand recognition.
Structured summary of protein interactions:
BRPF1 and H4K12ac bind by x-ray crystallography (View interaction)
BRPF1 and H2AK5ac bind by x-ray crystallography (View interaction)
H4K12ac and BRPF1 bind by isothermal titration calorimetry (1, 2, 3, 4, 5, 6, 7)
H2AK5ac and BRPF1 bind by isothermal titration calorimetry (1, 2, 3, 4, 5, 6, 7)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
In eukaryotic cells, in order to facilitate proper gene regulation
and nuclear organization, most of the genome is packaged into a
polymeric structure consisting of repetitive units of nucleosomes[1,2]. Each nucleosome consists of approximately 146 base pairs
of super-helical nuclear DNA folded around an octameric structure
of four core histone proteins: two H2A/H2B dimers and an H3/H4
tetramer [3]. These histone proteins contain an N-terminal tail
region and a C-terminal globular domain. The N-terminal histone
tails are presumably ﬂexible and protrude from the nucleosome
core [4]. These tail regions are also rich in lysine and, to a lesser
extent, arginine and serine [2], and are targets of numerous post-
translational modiﬁcations (PTMs) such as acetylation, methyla-
tion, phosphorylation, and ubiquitination, among others [4]. An
emerging model suggests that the collective combination of these
covalent PTMs regulate gene expression and has been termed the
‘‘histone code’’ [1,4–6].
Modulators of the ‘‘histone code’’ can be separated into three
groups which include the ‘‘writers’’, ‘‘erasers’’, and ‘‘readers’’ of
histone PTMs [7]. The ‘‘writers’’ and ‘‘erasers’ are enzymes such
as histone acetyltransferases (HATs), and histone deacetylases
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removing different PTMs. The epigenetic ‘‘readers’’ are proteins
that do not alter the histones, but rather discriminatively detect
PTMs located at speciﬁc positions on each histone. The regulation
of chromatin dynamics by these modulators dictates the outcome
of numerous nuclear processes including transcription, DNA repair,
recombination, and replication [8–11]. These processes are central
to cell homeostasis, as alterations in chromatin structure contrib-
ute to the development of cancer and other human diseases
[8,9,12].
In humans, the t(8;16)(p11;p13) translocation of the MOZ
(monocytic leukemia zinc-ﬁnger protein, also known as KAT6A or
MYST3) HAT is associated with a subtype of acute myeloid leuke-
mia (AML) with a particularly poor outcome [13,14]. In this abnor-
mality, the N-terminal region of MOZ is fused to the C-terminal
part of the transcription co-activator CREB binding protein (CBP)
[14]. MOZ has also been found translocated to the CBP homolog
p300 [15], to the transcriptional intermediary binding factor 2
(TIF2) [16], and to the nuclear receptor co-activator 3 (NcoA3)
transcription factor [17]. MOZ functions as a multi-subunit HAT
complex and acetylates free histones H3, H4, H2A and H2B
in vitro [18,19]. Acetylation of histones located near gene promot-
ers is associated with up-regulation of gene transcription, and the
acetylation activity of MOZ has been shown to control expression
of homeobox (HOX) genes [20]. The MOZ HAT also plays a direct
role in hematopoiesis and is essential for the development and
maintenance of hematopoietic stem cells (HSCs) [21].
MOZ forms a tetrameric complex with the inhibitor of growth 5
(ING5), hEAF6 (homolog of Esa1-associated factor 6), and the
bromodomain-PHD ﬁnger proteins (BRPF1, -2, or -3) (Fig. 1B)
[8,18]. BRPF proteins have been shown to bridge the association
of MOZ with ING5 and hEAF6, thereby promoting its acetyltrans-
ferase activity [18]. Deletion mapping studies also revealed that
the acetyltransferase domain of MOZ is sufﬁcient for BRPF1 inter-
action [18]. BRPF proteins therefore play a key role in assembling
and activating MOZ HAT complexes. BRPF1 contains a unique
combination of domains typically found in chromatin-associated
factors, including a double plant homeodomain (PHD) and zinc
ﬁnger (ZnF) assembly (PZP), a bromodomain, and a chromo/
Tudor-related Pro-Trp-Trp-Pro (PWWP) domain (Fig. 1A). PHD ﬁn-
gers are a conserved C3HC4 zinc ﬁnger motif commonly found in
nuclear proteins that regulate transcription and chromatin remod-
eling [22]. The ﬁrst PHD ﬁnger (PHD1) of BRPF2 has been shown to
recognize the unmodiﬁed histone H3 tail, while the second PHD
ﬁnger (PHD2) interacts non-speciﬁcally with DNA [23,24]. The
PWWP domain is necessary for the association of BRPF1 with con-
densed chromatin and is able to recognize H3K36me3 [25,26].
These domains within BRPF1, in concert with additional chromatin
reader domains located in other subunits of the complex, help
recruit MOZ to distinct sites of active chromatin [23,26].
Bromodomains are evolutionary conserved structural motifs
composed of about 110 amino acids that were ﬁrst identiﬁed in
the Drosophila protein brahma (hence the name ‘‘bromo’’), and
are generally known to recognize acetylated histone residues
[27]. All bromodomains share a conserved fold that comprises a
left-handed bundle of four a-helices (aZ, aA, aB, aC), linked by
loop regions of variable length (ZA and BC loops), which line the
acetyllysine (Kac) binding site and determine ligand-binding spec-
iﬁcity [28,29]. The BRPF1 bromodomain is a member of subfamily
IV of the human bromodomains (as deﬁned by the phylogenetic
tree generated by Filippakopoulos et al. [29]), which includes the
bromodomains of the BRD1, BRD7, BRD9, BRPF1/3, ATAD2 and
ATAD2b proteins. Although the three-dimensional structure of
each of these bromodomains is known [29,30], the speciﬁc histone
ligands recognized by these bromodomains, and the molecular
basis directing their substrate speciﬁcity is largely undiscovered.Our recent studies revealed the interaction of the BRPF1 brom-
odomain with multiple acetyllysine residues on the N-terminus of
histones, and demonstrated that it preferentially binds to the
H2AK5ac, H4K12ac and H3K14ac histone ligands [31]. However,
the molecular mechanism driving recognition of the acetylated
histone tails by the BRPF1 bromodomain has not been elucidated.
In this study, we present the X-ray crystal structures of the BRPF1
bromodomain in complex with two of its histone peptide ligands,
H2AK5ac and H4K12ac. Importantly this is the ﬁrst bromodomain
structure solved in complex with an H2AK5ac ligand. These struc-
tures were used to evaluate the relative contribution of speciﬁc
bromodomain binding site residues to ligand recognition via
site-directed mutagenesis coupled with isothermal titration calo-
rimetry (ITC). Through these studies we are able to describe the
molecular basis of histone acetyllysine recognition by the BRPF1
bromodomain for the ﬁrst time. A better understanding of this pro-
cess will ultimately be useful in the rational design of pharmaceu-
tical agents against acute myeloid leukemia and other cancers.
2. Materials and methods
2.1. Cloning, expression, and puriﬁcation of the BRPF1 bromodomain
Isolated cDNA from human BRPF1 was kindly provided by Dr.
Xiang-Jiao Yang. The BRPF1 bromodomain region (residues
629-742) was ampliﬁed and subcloned into the pDEST15 vector
(Invitrogen) as described previously [31]. BRPF1 bromodomain
mutants E36A, I88A, F89A, N83A, A84S, C79A, and N78A, were gen-
erated using the QuikChangemutagenesis procedure (Stratagene)
as described in Champagne et al. [32]. All mutants were produced
by conventional PCR using the pDEST15 plasmid containing the
BRPF1 bromodomain as a template. The DNA sequence for each
mutant was veriﬁed before being expressed in Escherichia coli
Rosetta™ 2(DE3)pLysS competent cells (Novagen).
The wild-type or mutant BRPF1 bromodomain proteins were
expressed in E. coli Rosetta™ 2 and puriﬁed essentially as described
in [31]. For ITC or circular dichroism (CD) experiments the 117 res-
idue BRPF1 bromodomain proteins (114 from the bromodomain
and -GPL from the N-terminal GST tag) were concentrated and dia-
lyzed into buffers consisting of 20 mM NaNH4 pH 7.0 and 150 mM
NaCl, or 50 mM NaNH4 pH 7.0 and 50 mM NaCl, respectively. For
X-ray crystallography the protein was further puriﬁed using gel ﬁl-
tration chromatography (HiPrep 16/60 Sephacryl S-100 High Reso-
lution, GE Healthcare) and equilibrated with wash buffer (20 mM
Tris pH 8.0, 150 mM NaCl and 1 mM DTT). The puriﬁed BRPF1
bromodomain was then concentrated to 69.9 mg/mL at 4 C for
crystallization experiments.
2.2. Crystallization
Prior to crystallization 2.3 mM of the puriﬁed BRPF1 bromodo-
main protein was mixed with 5 mM of either the H2A(res
1–12)K5ac or H4(res 4–17)K12ac (SGRG Kac QGGKARA or
GKGGKGLG Kac GGAKR, respectively) modiﬁed histone peptide in
a 1.5 mL microcentrifuge tube. Crystallization screens using the
sitting drop method were performed by mixing 1 lL of the pro-
tein–ligand solution with 1 lL of the reservoir solution in 96-well
VDX plates with a reservoir volume of 100 lL.
Crystals of the BRPF1 bromodomain bound to H2AK5ac grew at
4 C from Hampton Research Crystal Screen I condition number 26
(0.2 M NH4SO4, 0.1 M MES monohydrate pH 6.5, and 30% w/v poly-
ethylene glycol monomethyl ether (PEG) 5000). Initial crystals
were further optimized using the hanging drop method in 24 well
VDX plates (Hampton Research). The pH of all buffers was adjusted
with HCl or NaOH. The H2AK5ac crystals were improved through
seeding techniques and the addition of 1% propylene glycol to
Fig. 1. The BRPF1 bromodomain recognizes acetylated histones. (A) Schematic representation of domain modules within the human BRPF1 protein. (B) The MOZ/MORF HAT
complex. (C) A ribbon diagram of the human BRPF1 bromodomain (yellow) in complex with the histone H2AK5ac peptide (blue sticks). (D) Top view of the H2AK5ac peptide
in the binding pocket of the BRPF1 bromodomain. The structures were generated with Pymol [65].
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0.045 mm3 in a P21 space group with the unit cell parameters
a = 60.9 Å, b = 55.6 Å, c = 82.1 Å and b = 93.6. All crystals were
ﬂash cooled in liquid nitrogen at 100 K.
The H4K12ac bromodomain-ligand complex grew at 4 C from
Hampton Research Crystal Screen II, condition 30 (0.1 M HEPES
pH 7.5, 10% w/v polyethylene glycol (PEG) 6000, 5% v/v (+/)-2-
methyl-2,4-pentanediol (MPD)). Crystals were reproduced using
the hanging drop method in a 24 wells VDX plates (Hampton
Research) and grew to 0.35, 0.08, 0.03 mm3 in space group
P43212 with the unit cell parameters a=,b = 75.1 Å, c = 86.3 Å. The
H4K12ac-bromodomain crystals were cryoprotected by sequen-
tially transferring them into reservoir solution supplemented with
10% and 15% MPD before ﬂash freezing in liquid nitrogen at 100 K.
Additional details on the crystallization methods and initial data
collection can be found in Lubula et al. [33].
2.3. Data collection, structure determination and reﬁnement
The crystal diffraction data for both crystal forms was collected
on beamline X29 at the Brookhaven National Laboratory (BNL)
synchrotron at a wavelength of 1.075 Å. Data for the BRPF1bromo-H2AK5ac crystal were processed with the HKL-2000 soft-
ware package [34]. Data collection statistics are reported in Table 1.
The structure was solved using molecular replacement, and BRD1
(PDB ID 3RCW) was used as the starting model. Molecular replace-
ment was performed with HKL-3000 [35] integrated with MOLREP
[36] and selected programs from the CCP4 package [37]. ARP/wARP
[38] and BUCCANEER [39] were used to rebuild the initial model.
The model was later manually updated using COOT to add the
H2AKac histone ligand [40] and reﬁned with REFMAC [41]. MOL-
PROBITY [42] and ADIT [43] were used for structure validation.
The ﬁnal R-factor and R-free values of the model are 20.39% and
25.26%, respectively, for data from 41.02 Å to 1.80 Å. There was
clear electron density for residues 1–117 of the BRPF1 bromodo-
main in chains A, B, C and D, as well as for histone H2AK5ac resi-
dues 1–10 in chains E, F, G and H (peptide residues 11–12 had
no density observed).
Data for the BRPF1 Bromo-H4K12ac crystal were processed
with the HKL2000 software package, and the statistics are shown
in Table 1. The structure was solved by molecular replacement
using the ligand-free BRPF1 bromodomain structure (PDB code:
2D9E) as the starting model. Molecular replacement was per-
formed with PHASER [44] from the CCP4 package [37]. The PHENIX
Table 1
Crystallographic data collection and reﬁnement statistics of the BRPF1 bromodomain
in complex with H2AK5ac and H4K12ac.
Bromodomain +
H4K12ac
Bromodomain +
H2AK5ac
No. of crystals 1 1
Beamline BNL X29 BNL X29
Wavelength (Å) 1.075 1.075
Detector ADSC Quantum-315r
CCD
ADSC Quantum-315r
CCD
Crystal-to-detector distance
(mm)
250 225
Rotation range per image () 1 0.5
Total rotation range () 360 284
Exposure time per image (s) 12 12
Resolution range (Å) 34.43–1.94 41.02–1.80
Space group P43212 P21
Unit cell parameters
a, b, c (Å) 75.1, 75.1, 86.3 60.9, 55.6, 82.1
a, b, c () 90.0, 90.0, 90.0 90.0, 93.6, 90.0
Unique reﬂections 18780 48421
Rwork/Rfree (%) 17.55/21.29 20.39/25.26
Redundancy 27.7 (27.2) 4.0 (3.9)
Mean I/r (I) 25.84 (14.66) 21.04 (3.0)
Completeness (%) 99.6 (96.9) 99.9 (100)
Rmerge
* (%) 13.9 (27.9) 8.1 (38.6)
Wilson B factor (Å2) 26.5 21.0
Number of non-hydrogen atoms
Protein 997 4267
Water 143 722
RMSD
Bond lengths (Å) 0.007 0.019
Bond angles () 0.95 1.78
Ramachandran plot
Residues in most favored regions 93.5% 94.0%
Residues in additional allowed
regions
5.6% 6.0%
Residues in generously allowed
regions
0.9% 0.0%
Residues in disallowed regions 0.0% 0.0%
* Rmerge = SUM (ABS(I  <I>))/SUM (I).
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modiﬁcation. The H4K12ac peptide bound to the BRPF1 bromodo-
main molecule was built into the density map using the COOT pro-
gram [40] and the structure of the complex was reﬁned against
1.94 Å diffraction data with simulated annealing and restraint min-
imization methods using the PHENIX [45] program. PROCHECK
[46], MOLPROBITY [42] and ADIT [43] were used for structure val-
idation. The ﬁnal R-factor and R-free values of the model are
17.55% and 21.29%, respectively, for data from 34.43 Å to 1.94 Å.
There was clear electron density for residues 4–117 of the BRPF1
bromodomain (chain A), and for residues 6–13 (chain B) in the his-
tone H4K12ac ligand. H4K12ac histone peptide residues 11, 12 and
14–17 had no observable density.
2.4. Isothermal titration calorimetry
ITC experiments were carried out at 5 C with a MicroCal ITC200
instrument (GE Healthcare). Each of the BRPF1 bromodomain
mutant proteins and histone peptide samples were dialyzed into
a 20 mM NaH2PO4–Na2HPO4 (pH 7.0) and 150 mM NaCl buffer.
Calorimetric titration was performed by titrating each histone tail
ligand (5 mM) into 0.2 mM of the mutant BRPF1 bromodomain
protein in the sample cell in a series of 19 individual injections
of 2 lL, at time intervals of 150 s. These were preceded by a
preliminary injection of 0.5 lL of the 5 mM peptide sample. To
determine the heat of dilution of the titrant peptides in the
experimental buffer, control experiments were conducted underidentical conditions. As part of data analysis, this was deducted
from the experimental data. The obtained change-in-heat peaks
were then analyzed by the Origin 7.0 program (OriginLab Corpora-
tion) and used to calculate binding afﬁnities. Experiments in which
binding occurred were performed in triplicate, while non-binding
experiments were performed in duplicate.2.5. Circular dichroism spectroscopy
Circular Dichroism (CD) spectra were recorded on a JASCO J-815
CD Spectrometer (JASCO, Japan) at 25 C in a 1.6 cm cell. BRPF1
bromodomain wild type (WT) or mutant proteins were dialyzed
in 50 mM NaH2PO4–Na2HPO4 pH 7.0, 50 mM NaCl and diluted to
between 0.1 lM and 0.5 lM in concentration. CD spectra were
measured from 199 to 260 nm. Two spectra were measured and
averaged for each mutant bromodomain protein sample and the
wild-type protein. Spectra were analyzed using the K2D3 [47,48]
structure prediction software to determine the percent a-helical
and b-sheet content.3. Results and discussion
3.1. Overall structure of the BRPF1 bromodomain
As discussed above, the BRPF1 subunit is part of the MOZ HAT
complex, and it contains multiple chromatin reader domains
known to direct the MOZ acetyltransferase activity to chromatin
substrates [18,49]. To further understand the role of the bromodo-
main in recruiting BRPF1 to histones it is imperative to character-
ize the molecular mechanism of BRPF1 bromodomain-mediated
acetyllysine recognition. To this end we determined the crystal
structures of the BRPF1 bromodomain in complex with its
H2A(1–12)K5ac and H4(4–17)K12ac histone peptide ligands (PDB
IDs 4QYL and 4QYD, respectively). The crystallographic data
collection and reﬁnement statistics are listed in Table 1. The
bromodomain of BRPF1 in complex with the H2AK5ac peptide
crystallized in a monoclinic space group P21, with four protein–
ligand complexes in the crystallographic asymmetric unit, while
the BRPF1 bromo-H4K12ac structure was in a tetragonal space
group P43212 with only one protein–ligand complex in the asym-
metric unit. Both of the crystal structures were solved by molecular
replacement using the unpublished bromodomains of Peregrin for
the H4K12ac structure (PDB ID 2D9E) and BRD1 for the H2AK5ac
structure (PDB ID 3RCW) as the initial models, respectively. In
the crystal containing the H2AK5ac ligand, the four protein mono-
mers are in identical conformations and are superimposable on
each other with RMSD values of 0.15–0.18 Å over 117 pairs of
identical Ca atoms [50]. The BRPF1 bromodomain bound to
H4K12ac (Chain A) is also in the same conformation as the
H2AK5ac-bound structure (Chain D) with an RMSD of 0.94 Å over
113 identical Ca atoms [50]. The overall architecture of the BRPF1
bromodomains exhibit structural features characteristic of other
bromodomain modules and contain the typical left-handed
four-helix bundle topology (Fig. 1C). These four helices, sequen-
tially named aZ, aA, aB, aC, respectively (from the N-terminus),
are connected by two loops: a long loop connecting helices aZ
and aA (the ZA loop) and a short loop connecting helices aB and
aC (the BC loop). The ZA loop is packed against the BC loop to form
a hydrophobic pouch that constitutes the binding pocket. Fig. 1C
shows the side view of the 1.8 Å BRPF1 bromo-H2AK5ac complex
and depicts the overall bromodomain fold. Fig. 1D shows the top
view where the H2AK5ac ligand is oriented between the ZA and
BC loops with the acetylated lysine protruding down into the deep
binding pocket formed between the four alpha-helical bundle.
Structural alignment of the H2AK5ac- and H4K12ac-bound BRPF1
Fig. 2. Coordination of the H2AK5ac and H4K12ac histone ligands by the BRPF1 bromodomain. (A) The BRPF1 bromodomain (yellow) in complex with H2AK5ac (blue) ligand.
Hydrogen bonds are indicated by a red dotted line. (B) The BRPF1 bromodomain (yellow) in complex with the H4K12ac (green) ligand. (C) The Fo-Fc omit map representing
the bound histone H2AK5ac peptide (blue) in complex with the BRPF1 bromodomain (yellow) contoured at 1r. (D) The Fo-Fc omit map representing the bound histone
H4K12ac peptide (green) in complex with the BRPF1 bromodomain (yellow) contoured at 1r. (E) Surface representation of the H2AK5ac binding groove. (F) Surface
representation of the H4K12ac ligand binding pocket.
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(PDB ID 2D9E) produces an RMSD of 0.652, which indicates that no
major conformational changes in the overall fold of the bromodo-
main occurs upon ligand binding.3.2. Acetyllysine coordination of H2AK5ac and H4K12ac
The crystal structures of the BRPF1 bromodomain in complex
with the H2AK5ac and H4K12ac histone peptide ligands reveal that
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of H-bond interactions (Fig. 2A and B). As observed in other brom-
odomains, and our previous molecular dynamic models of the
BRPF1 bromo–ligand interaction, the acetyllysine residue of the
histone peptides is deeply inserted into the hydrophobic binding
pocket of the BRPF1 bromodomain (Fig. 2E and F) [27,31,51]. In this
pocket, the carbonyl oxygen of the N-acetyl group on both the
H2AK5ac and H4K12ac histone peptide ligands forms a H-bond
interaction with the amide nitrogen of the N83 residue in the
BRPF1 bromodomain (Fig. 2A and B). This particular interaction is
highly conserved among bromodomains and is the major mode
of recognition of the acetylated histone ligand [28]. The impor-
tance of the direct hydrogen bond between bromodomain residue
N83 and the acetylated lysine moiety is highlighted by the com-
plete loss of ligand binding observed when N83 is mutated to ala-
nine (Fig. 3A and B, red trace, Supplemental Figs. 1–3). In both
structures, acetyllysine coordination is also stabilized by H-bond
contacts through ordered water molecules in the binding pocket.
The carbonyl oxygen of the acetyllysine moiety is connected to res-
idue Y40 through water (w1), while the e-amino group forms a
hydrogen bond to the backbone carbonyl of I27 mediated by
another water molecule (w2).
3.3. Molecular mechanism of histone ligand recognition
In the H2AK5ac-bound structure, in addition to the acetyllysine
contacts described above, there was clear electron density for the
ﬁrst ten residues in the histone peptide (Fig. 2C), with only
Arg11 and Ala12 unordered. The median B factor for the H2AK5ac
ligand (10 residues) is 25 Å2 for chains E, F, G and H, respectively,
and all modeled residues have an average occupancy of more than
90%. Other bromodomain–ligand contacts observed in this com-
plex include hydrogen bonds between D39, H43 and Y82 of the
BRPF1 bromodomain to the backbone amino group of Arg3, the
backbone carbonyl of Gly2, and the backbone amino of Gly4 in
the histone peptide, respectively (Fig. 2A). There are also two
important hydrophobic interactions between F89 and I88 of the
bromodomain and Gly7 and Gly8 in the histone ligand.
In the H4K12ac-bound structure there was clear electron den-
sity for eight of the fourteen histone peptide residues (Fig. 2D).
In addition to the acetyllysine contacts, hydrogen bonds are
observed between D39 and Y82 in the BRPF1 bromodomain to
the backbone amino groups of Leu10 and Gly11, respectively.
There are also two hydrogen bonds between the e-amino group
of Lys8 in the H4K12ac peptide and the backbone carbonyls of
L80 and N83 of the bromodomain. The hydrophobic residues F89
and I88 are positioned in the bromodomain binding pocket to con-
tact peptide residues Gly14 and Ala15, but these two residues in
the H4K12ac ligand were unordered, with no observed density
(also missing from the density map were residues Gly4, Lys5,
Lys16 and Arg17). The median B factor for the H4K12ac ligand (8
residues) is 31 Å2, and all modeled residues have an average occu-
pancy greater than 90%.
The extensive network of intermolecular contacts observed
between the BRPF1 bromodomain and histone peptide residues
adjacent to the acetyllysine in both the H2AK5ac and H4K12ac
ligand-bound structures indicates that these interactions play a
role in the binding speciﬁcity. The hydrophobic contact between
F89 and the Kac +2 position in the histone peptide (Gly7 in
H2AK5ac, and Gly14 in H4K12ac) also appears to be a critical com-
ponent of histone recognition as demonstrated by the complete
loss of ligand binding in the F89A mutant (Fig. 3A and B, cyan trace,
Supplemental Figs. 1–3). The F89 residue is located at the entrance
of the acetyllysine binding pocket and is positioned to make
additional hydrophobic contacts with the methylene groups in
the acetyllysine side chain (Fig. 2A and B). To further elucidatethe molecular mechanism driving recognition of the H2AK5ac
and H4K12ac acetylated histone peptides by the BRPF1 bromodo-
main, we designed four additional mutant proteins with point
mutations at A84S, E36A, I88A and C79A (Fig. 3E). Each of these
residues are located proximal to the acetyllysine binding pocket,
and were selected based on an observed direct contact with the
histone ligand in the crystal structure or on the presence of signif-
icant chemical shift changes displayed in our previously published
nuclear magnetic resonance (NMR) titration studies [31]. Once
expressed, these mutant BRPF1 bromodomain proteins were ana-
lyzed using ITC to measure their effect on ligand binding afﬁnities
as compared to the wild type (WT) protein. Of note, the mutations
introduced into the BRPF1 bromodomain did not cause any signif-
icant change in the overall structure, or unfolding of the mutant
proteins. This is demonstrated by the circular dichroism (CD) spec-
troscopy studies we performed on each of the wild-type and
mutant proteins. As depicted in Fig. 3D and Table 2, there is a less
than 6% change in a-helical content observed between the WT and
mutant BRPF1 bromodomain proteins.
Residue C79 is located at the bottom of the hydrophobic bind-
ing pocket of the BRPF1 bromodomain, and although it does not
make a direct contact to the acetylated lysine, the C79A mutation
results in a 2.5–5-fold loss of binding afﬁnity with the H2AK5ac
and H4K12ac ligands, likely due to changes in the binding pocket
composition or electrostatics. The I88A mutation has a similar
effect on the ligand binding afﬁnity as the C79A mutation, but this
residue plays an important role in making hydrophobic contacts to
the backbone residues of the histone ligands as observed in the
crystal structures. As might be expected based on the structures,
the E36A and A84A mutations located more distal to the acetylly-
sine binding pocket had relatively moderate affects on histone
binding afﬁnity. Interestingly, E36A showed a strong chemical shift
change upon binding of the histone binding in our previous NMR
experiments suggesting this residue might be critical for ligand
coordination [31]. However, the examination of the crystal struc-
tures reveals that E36 does not directly contact the histone pep-
tides. Instead, the E36 side chain changes conformation in the ZA
loop to accommodate histone ligand binding (Fig. 4A). These obser-
vations concur with previous studies that have shown the ligand
binding selectivity of bromodomains is driven by a network of
interactions that coordinate both the acetyllysine and surrounding
histone peptide residues [30,51–53].
As seen with other chromatin reader domains, histone ligand
binding does not induce major conformational changes in the
BRPF1 bromodomain. Structural alignment of the apo BRPF1 brom-
odomain structure solved by NMR (PDB ID 2D9E), with the
H2AK5ac- and H4K12ac-bound structures, reveals only minor
adjustments in the side chains of amino acid residues in the bind-
ing pocket (Fig. 4A). Residues I88 and F89 are re-oriented to make
hydrophobic contacts to the peptide backbone and the methylene
groups of K5ac and K12ac, respectively. The side chain of D39 ﬂips
into the binding pocket to form a hydrogen bond to the histone
peptide. Residues Y40 and Y82 also make slight conformational
changes to accommodate hydrogen bond formation to the ligands
(Fig. 4A).
3.4. Comparison with other BRPF1 bromodomain–ligand models
An unpublished NMR structure of the BRPF1 bromodomain in
complex with the H4K5ac ligand is deposited in the PDB (PDB ID
2RS9). In this structure the acetyllysine is coordinated by an
H-bond contact between the carbonyl oxygen of the N-acetyl
group of the histone H4K5ac ligand and the amide nitrogen of
the N83 residue in the BRPF1 bromodomain. However, when com-
pared to our BRPF1 bromo-H4K12ac structure, the H4K5ac ligand
is oriented in the opposite direction in the binding pocket, with
Fig. 3. ITC measurements of interactions between mutant BRPF1 bromodomain proteins and histone tail ligands. (A) Superposed exothermic ITC enthalpy plots for the
binding of the BPRF1 bromodomain wild type and mutant proteins to the H2A(1–12)K5ac peptide. The insert lists the measured binding constants. (B) Superposed
exothermic ITC enthalpy plots for binding of the BRPF1 bromodomain wild type and mutant proteins to the H4(4–17)K12ac peptide. The insert lists the measured binding
constants. (C) Superposed exothermic ITC enthalpy plots for the binding of the BRPF1 bromodomain wild type and mutant proteins to the H4(4–17) unmodiﬁed peptide. The
insert lists the measured binding constants. (D) Circular dichroism spectra in the far-UV region of the BRPF1 bromodomain wild type and mutant proteins. The percent alpha-
helical content of each protein is listed in the insert. (E) Surface representation of the BRPF1 bromodomain showing speciﬁc point mutations introduced into the binding
pocket by site-directed mutagenesis and the superimposed structures of the histone ligands in the binding pocket. The two BRPF1 bromodomain structures were
superimposed using Pymol [65].
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than at the Kac +2 position (Gly14). There are also no additional
hydrogen bonds observed between adjacent residues in the
H4K5ac histone peptide and the BRPF1 bromodomain structure,
which could be attributed to the relatively weak 1.2 mM binding
afﬁnity the bromodomain has for this ligand [31].
Previously, we published the results of molecular dynamic (MD)
simulation experiments to predict the ligand binding contacts
between the BRPF1 bromodomain and its histone ligands [31].
The hydrogen bond contacts between the BRPF1 bromodomain
N83 residue and acetyllysine in the H2AK5ac and H4K12ac histone
ligands are conserved between the crystal structures and the MD
models of ligand coordination. However, the prediction of hydro-
gen bond contacts between the histone peptides and the BRPF1
bromodomain were limited because ordered waters in the binding
pocket were not depicted in the MD simulations. We were unable
to model these interactions since the unpublished NMR structures
available for the BRPF1 bromodomain (PDB ID 2RS9 and 2D9E) did
not contain information about water molecules.
Recently, Vidler et al. discussed the importance of ﬁve ordered
water molecules, which appear to be a conserved feature of the
bromodomain binding pocket [54]. They observed that these
ordered waters are found in deposited bromodomain crystal struc-
tures regardless of the presence or absence of a bound ligand,
suggesting that water plays a signiﬁcant role in the structural com-
position of the binding pocket, and affects the selectivity and
modality of ligand binding [54]. We carried out structural align-
ments of the ligand-free (‘‘apo’’) structures of the human PCAF
bromodomain (PDB ID 3GG3) and the BRD1 bromodomain (PDB
ID 3RCW), to compare them with the ligand-bound (‘‘holo’’) struc-
ture of the ﬁrst bromodomain of BRD4 (PDB ID 3UVX) and our crys-
tal structures the BRPF1 bromodomain (in complex with the
H2AK5ac and H4K12ac ligands). Analysis of these structures
reveals that the water mediating a hydrogen bond between the
hydroxyl group of Y40 and the carbonyl oxygen of the acetyllysine
moiety (w1 in Fig. 2A and B) is present in the binding pocket
regardless of the absence or presence of the ligand. Conversely,
the second water in our crystal structures (w2 in Fig. 2A and B)
is absent in the apo structures, and this water is only seen in the
holo structures where it bridges between a backbone carbonyl of
the bromodomains to the epsilon nitrogen of the acetylated lysine
in the histone ligands. This suggests that the ordered waters in the
bromodomain binding pocket contribute to the molecular mecha-
nism driving binding of the histone H2AK5ac and H4K12ac ligands
in the BRPF1 bromodomain, and may be a conserved mode of ace-
tyllysine recognition for other bromodomains as well.
3.5. Comparison with other bromodomain subfamilies
Despite the low degree of overall sequence homology, bromod-
omains have a highly conserved overall structural fold comprising
four a-helices (aZ, aA, aB, and aC) linked by highly variable loop
regions (ZA and BC loops) that form a hydrophobic binding pocketTable 2
Percentages of a-helix and b-strand composition in wild type (WT) and mutant BRPF1
proteins calculated from circular dichroism experiments.
Protein % a-Helix* % b-Strand*
BRPF1 WT 63.23 2.54
BRPF1 A84S 68.21 1.49
BRPF1 E36A 69.28 1.27
BRPF1 I88A 54.45 6.99
BRPF1 C79A 54.83 7.36
BRPF1 F89A 64.86 1.48
BRPF1 N83A 65.10 1.61
* The % a-helix and b-strand were calculated using the program K2D3 [47].[27]. However, the surface properties of bromodomains have been
shown to be highly diverse [29]. The electrostatic potential of the
surface area around the acetylated lysine binding pocket ranges
from highly positively to strongly negatively charged, suggesting
that individual bromodomains recognize largely different ligands
[29]. Furthermore, it has been suggested that bromodomain
peptide recognition is dependent on the pattern of multiple PTMs
rather than on a single acetylation site [29]. Bromodomains in dif-
ferent subfamilies are therefore expected to use a variety of recog-
nition modes to select for their particular acetylated histone
ligand(s).
Currently there are no other bromodomain structures in com-
plex with a histone H2AK5ac ligand deposited into the PDB, but
the structure of the second bromodomain of the BRD2 in complex
with H4K12ac has been solved. BRD2 belongs to the human BET
family of bromodomains in subfamily II, which also includes
BRD3, BRD4 and BRDT, and these proteins have a unique architec-
ture with two tandem bromodomains and a conserved extra-
terminal domain [55]. In the intact nuclei, the BET protein BRD2
activates transcription by targeting histone H4K12ac, one of the
active marks of chromatin [55]. BRD2 has also been shown to bind
to the histone H4K5ac peptide, and more weakly recognizes the
histone H4K16ac and H3K9ac modiﬁcations [55]. Although the
BRD2 and the BRPF1 bromodomains belong to two separate sub-
families, the modality of histone H4K12ac recognition is similar.
Fig. 4B shows the structural alignment of the BRPF1 and BRD2
(PDB ID 2DVQ) bromodomains bound to the H4K12ac peptide.
The RMSD of these two structures is 1.4, mainly due to slight con-
formational changes in the alpha-helical regions. In the bromodo-
main binding pocket, the histone H4K12ac ligand backbone is
oriented in the same direction in both structures, and the amino
acid side chains coordinating the histone peptide are in nearly
identical conformations. In both structures, the acetyllysine side
chain of H4K12ac sits in the deep hydrophobic binding pocket. In
BRD2, the N-acetyl group of K12ac is positioned so the carbonyl
forms a hydrogen bond with the amide group of N156. The hydro-
gen bond network coordinating the acetyllysine through two
ordered waters (w1 and w2) is also conserved between the BRPF1
and BRD2 bromodomain structures, with only slight shifts in loca-
tion of the waters to accommodate the orientation of the acetylly-
sine side chain in the binding pocket. The acetylated lysine of
H4K12 as is also surrounded by the hydrophobic residues P98
(I27), I162 (F89) in BRD2 [55], which contribute to the binding
pocket formation and modality of ligand selection in the same
way we observe for the BRPF1 bromodomain.
Interestingly, BRD4 bromodomain has been shown to coordi-
nate the H4K12acK16ac double modiﬁcation (PDB ID 3UVX,
Fig. 4C) [29]. Coordination of the K12ac is consistent with what
is observed in the BRPF1 and BRD2 bromodomain structures
(Fig. 4A and B). However, the H4K16ac is bound in an adjacent
hydrophobic pocket formed by P82, W81 and I146 in the BRD4
structure. In the BRPF1 structure W81 is a charged asparagine
(N26), while a more ﬂexible isoleucine side chain in BRD4 (I146)
replaces F89 in the BRPF1 bromo structure. These two amino acid
substitutions create critical hydrophobic contacts necessary for
coordination of the second H4K16ac group, which would likely
not be possible in the BRPF1 bromodomain. Importantly, the two
ordered waters are also observed in the H4K12ac binding pocket
of the BRD4 bromodomain structure, and coordinate the carbonyl
oxygen and epsilon nitrogen of the K12ac moiety as described
above. Thus, these two ordered waters appear to be a general fea-
ture of the H4K12ac ligand binding mechanism.
The PCAF and CBP/p300 bromodomains, which belong to the
ﬁrst and third bromodomain subfamilies, are able to recognize his-
tone H3K36ac and H4K20ac peptide ligands, respectively. The NMR
solution structures of these bromodomains in complex with their
Fig. 4. Structural comparison of bromodomain ligand coordination. (A) The BRPF1 bromodomain (yellow) in complex with H2AK5ac (blue) ligand, or in complex with the
H4K12ac (green) ligand. The BRPF1 bromodomain structure is superimposed onto the ‘apo’ BRPF1 bromodomain structure (magenta) using Pymol [65]. Hydrogen bonds are
indicated by a red dotted line, and water molecules in the ligand-bound structures are indicated by red spheres and labels. (B) The BRPF1 bromodomain (yellow) in complex
with the H4K12ac (green) ligand superimposed onto the BRD2 bromodomain crystal structure (green, PDB ID 2DVQ) in complex with the H4K12ac ligand (blue). Water
molecules from the BRPF1 structure are indicated by red spheres and labels, and green spheres with black labels indicate water molecules from the BRD2 structure. (C) The
BRPF1 bromodomain (yellow) in complex with the H4K12ac (green) ligand superimposed onto the BRD4 bromodomain crystal structure (blue, PDB ID 3UVX) in complex with
the diacetylated histone H4K12acK16ac ligand (orange). Water molecules from the BRPF1 structure are indicated by red spheres and labels, and water molecules from the
BRD4 structure are indicated by blue spheres with black labels. Residue numbering is for the BRPF1 bromodomain, except where indicated by corresponding colors.
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their acetylated histone ligands [53]. PCAF has been shown to pref-
erably interact with acetylation sites with a hydrophobic residue at
(Kac +1) position and a positively charged or aromatic residue at
(Kac +3) [53]. On the other hand, the CBP bromodomain has been
shown to favor bulky hydrophobic residues at (Kac +1) and (Kac
+2), a positively charged residue at (Kac 1), and an aromatic res-
idue at (Kac 2) [53]. Despite the variability in the mode of acety-
lated histone recognition, all bromodomains have been shown to
coordinate the acetylated lysine moiety via H-bond interactions
to the highly conserved asparagine in the binding pocket. However,
the ordered water molecules are not observed in these structures
since they were solved using NMR techniques.
3.6. BRPF1 bromodomain as a drug target
As mentioned previously, the t(8;16)(p11;p13) translocation of
the MOZ HAT complex contributes to the progression of AML
[14,56,57]. In this abnormality, the MOZ N-terminal domain fuses
to the C-terminal part of the CBP transcriptional co-activator result-
ing in highly active complex [18]. The BRPF proteins have been
shown to bridge the association of MOZ with ING5 and hEAF6,
thereby promoting MOZ acetyltransferase activity [18]. The BRPF1
subunit continues to associate with the MOZ HAT complex evenin the translocated proteins and thereby plays an important role
in MOZ-related regulation of transcription, hematopoiesis, leuke-
mogenesis, and other developmental processes [18,58]. Our results
indicate that the BRPF1 bromodomain contributes to recruiting the
MOZ complex to distinct sites of active chromatin. Thus, preventing
this process may be a useful tool in helping patients suffering from
MOZ-associated AML. Inhibitors of human bromodomains are cur-
rently under intense investigation as a potential therapeutic strat-
egy in multiple disease types [59,60]. In one study, a short hairpin
RNA screen suggested that inhibition of the BRD4 bromodomain
might be an effective treatment for AML [61]. Furthermore, an
inhibitor of the BET family of bromodomains, JQ1, is currently
under study as a potential drug for HIV reactivation, heart disease,
and as a non-hormonal male contraceptive [62–64]. In a computa-
tional analysis of bromodomains by Vidler et al., the BRPF1 brom-
odomain was classiﬁed as being ‘‘druggable’’ based on signature
residues in its binding pocket [54]. The structural data and muta-
tional analysis presented here are an important step in outlining
the molecular basis of histone acetyllysine recognition by the
BRPF1 bromodomain. A better understanding of this process will
ultimately be useful in the rational design of pharmaceutical agents
to treat AML and other cancers.
In conclusion, the results presented offer important insights
into the role of the bromodomain in recruiting BRPF1, and
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better understand the modality by which the BRPF1 bromodomain
interacts with its ligands, we solved the crystal structures of the
BRPF1 bromodomain in complex with its H2AK5ac and H4K12ac
histone ligands. These structures reveal that a network of H-bond
and hydrophobic contacts coordinate the acetyllysine moiety and
make speciﬁc contacts to ﬂanking residues in the histone tail. We
also identiﬁed two ordered water molecules in the binding pocket,
which mediate coordination of the acetyllysine moiety. To gain a
better understanding of the molecular mechanism driving speciﬁc-
ity, we also carried out site-directed mutagenesis in combination
with ITC studies. Our results indicate that the two most important
contacts for ligand coordination include the highly conserved N83
residue, which coordinates the acetyllysine directly, as well as F89,
which creates a critical hydrophobic contact with the histone tail
and shapes the bromodomain binding pocket wall. Our results
reinforce previous studies showing that ligand selectivity of brom-
odomains is a composite of both the acetylated lysine residue coor-
dination, and contacts to peptide residues ﬂanking the acetyllysine
in the histone tail. The BRPF1 bromodomain interacts with a region
of MOZ that remains intact after leukemic translocations. Thus, the
structural and functional characterization of the BRPF1 bromodo-
main–histone interaction is important for unraveling its role in
modulating the genomic binding targets of the MOZ HAT, and for
the development of future therapeutics for MOZ-related
leukemias.
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